Hydroxamic and carboxylic acid derivatives

Details Hydroxamic and carboxylic acid derivatives Hydroxamic and carboxylic acid derivatives

2000-03-22

2002-10-15

Shah, Mukund J. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S252180, C514S309000, C514S312000, C514S331000, C514S469000, C514S575000, C544S360000, C544S383000, C546S141000, C546S153000, C546S233000, C546S234000, C546S331000, C549S467000, C562S622000, C562S623000

Reexamination Certificate

active

06465468

ABSTRACT:

FIELD OF THE INVENTION
This invention relates to hydroxamic and carboxylic acid derivatives, and to their use in medicine.
BACKGROUND OF THE INVENTION
Metalloproteinases, including matrix metalloproteinase (MMP), (human fibroblast) collagenase, gelatinase and TNF&agr; convertase (TACE), and their modes of action, and also inhibitors thereof and their clinical effects, are described in WO-A-96/11209, WO-A-97/12902 and WO-A-97/19075, the contents of which are incorporated herein by reference. MMP inhibitors may also be useful in the inhibition of other mammalian metalloproteinases such as the ADAM or ADAM-TS families. Members of the ADAM family include TNF&agr; convertase (TACE) and ADAM-10, which can cause the release of TNF&agr; from cells, and others, which have been demonstrated to be expressed by human articular cartilage cells and also involved in the destruction of myelin basic protein, a phenomenon associated with multiple sclerosis.
Compounds which have the property of inhibiting the action of metalloproteinases involved in connective tissue breakdown, such as collagenase, stromelysin and gelatinase, have been shown to inhibit the release of TNF&agr; both in vitro and in vivo. See Gearing et al (1994), Nature 370:555-557; McGeehan et al (1994), Nature 370:558-561; GB-A-2268934; and WO-A-93/20047. All of these reported inhibitors contain a hydroxamic acid zinc-binding group, as do the imidazole-substituted compounds disclosed in WO-A-95/23790. Other compounds that inhibit MMP and/or TNF&agr; are described in WO-A-95/13289, WO-A-96/11209, WO-A-96/035687, WO-A-96/035711, WO-A-96/035712 and WO-A-96/03 5714.
WO-A-98/38859 discloses sulfonyl-divalent aryl/heteroaryl hydroxamic compounds as MMP inhibitors. In addition to the claimed compounds, it discloses related compounds including N-hydroxy-2-[[4-(phenylmethyl)-1-piperidinyl]sulfonyl]benzamide, as having inferior properties.
Probenecid, i.e. 4-[(dipropylamino)sulfonyl]benzoic acid, has long been known as a uricosuric agent; see U.S. Pat. No. 2,608,507. Certain metabolites are reported by Israeli et al, J. Med. Chem. 15(7):709-13 (1972).
SUMMARY OF THE INVENTION
The invention encompasses novel compounds of formula (I) which are useful ihibitors of matrix metalloproteinase, ADAM or ADAMTS enzymes, and which are useful for the treatment of diseases mediated by those enzymes and/or TNF&agr; mediated diseases, including degenerative diseases and certain cancers.
Novel compounds according to the invention are of the general type represented by formula (1):
(B)
2
N—X—(CH
2
)
m
—W—(CR
1
R
2
)
n
—COY  (I)
wherein
n=0-1;
m=0-1;
X is S(O)
1-2
;
Y is OH or NHOH;
W is aryl or heteroaryl;
R
1
is H, OR
7
or a group (optionally substituted with R
3
) selected from C
1-6
alkyl, C
2-6
alkenyl, C
2-6
alkynyl, aryl, C
1-6
alkyl-aryl, heteroaryl, C
1-6
allyl-heteroaryl, cycloalkyl, C
1-6
alkyl-cycloalkyl, heterocycloalkyl, C
1-6
alkyl-heterocycloalkyl; and
R
2
is H or C
1-6
alkyl;
or CR
1
R
2
is cycloalkyl or heterocycloalkyl optionally substituted with R
3
or a group (optionally substituted with R
3
) selected from C
1-6
alkyl, aryl, C
1-6
alkyl-aryl, heteroaryl, C
1-6
; alkyl-heteroaryl;
R
3
is OR
7
, COR
7
, CO
2
R
8
, CON(R
7
)
2
, N(R
7
)
2
, NR
7
COR
7
, NR
7
CON(R
7
)
2
, NR
7
CO
2
R
8
, NR
7
SO
2
R
8
, S(O)
0-2
R
8
, SO
2
N(R
7
)
2
or cycloimidyl (optionally substituted with R
4
);
R
4
is C
1-6
alkyl;
B is H or a group (optionally substituted with R
5
or R
6
) selected from C
1-6
alkyl, C
2-6
alkenyl, C
2-6
alkynyl, aryl, C
1-6
alkyl-aryl, heteroaryl, C
1-6
alkyl-heteroaryl, cycloalkyl, C
1-6
alkyl-cycloalkyl, heterocycloalkyl, C
1-6
alkyl-heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl; and each instance of B may be the same or different;
R
5
is a group (optionally substituted with R
6
) selected from C
1-6
alkyl, aryl, C
1-6
alkyl-aryl, heteroaryl, C
1-6
alkyl-heteroaryl, cycloalkyl, C
1-6
alkyl-cycloalkyl, heterocycloalkyl and C
1-6
alkyl-heterocycloalkyl;
or B—N—B is heterocycloalkyl optionally substituted with R
5
, R
6
, ═O or ═NOR
5
;
R
6
is a group selected from N(R
7
)
2
, NR
7
COR
7
, NR
7
CON(R
7
)
2
, NR
7
CO
2
R
8
, NR
7
SO
2
R
8
, OR
7
, COR
7
, CO
2
R
4
, CON(R
7
)
2
S(O)
0-2
R
8
, and SO
2
N(R
7
)
2
;
R
7
is H or a group selected from C
1-6
alkyl, aryl, C
1-6
alkyl-aryl, heteroaryl, C
1-6
alkyl-heteroaryl, cycloalkyl, C
1-6
alkyl-cycloalkyl, heterocycloalkyl and C
1-6
alkyl-heterocycloalkyl, wherein said group is optionally substituted with R
8
, COR
8
, SO
0-2
R
8
, CO
2
R
8
, OR
8
, CONR
4
R
8
, NR
4
R
8
, or SO
2
NR
4
R
8
and for each case of N(R
7
)
2
the R
7
groups are the same or different or N(R
7
)
2
is heterocycloalkyl optionally substituted with R
8
, COR
8
, SO
0-2
R
8
, CO
2
R
8
, OR
8
, CONR
4
R
8
, NR
4
R
8
, or SO
2
NR
4
R
8
;
R
8
is C
1-6
alkyl, aryl, C
1-6
alkyl-aryl, heteroaryl or C
1-6
alkyl-heteroaryl; and the salts, solvates, hydrates, N-oxides, protected amino, protected carboxy and protected hydroxamic acid derivatives thereof
Many compounds of formula I are new.
DESCRIPTION OF THE INVENTION
Preferred compounds of the invention are those wherein X is SO
2
; Y is NHOH and/or B—N—B is optionally substituted heterocycloalkyl. Other preferences are defined in the subclaims.
It will be appreciated that the compounds according to the invention can contain one or more asymmetrically substituted carbon atoms. The presence of one or more of these asymmetric centres in a compound of formula (I) can give rise to stereoisomers, and in each case the invention is to be understood to extend to all such stereoisomers, including enantiomers and diastereomers, and mixtures including racemic mixtures thereof.
It will further be appreciated that the compounds according to the invention may contain an oxime. This oxime can give rise to geometrical isomers, and in each case the invention is to be understood to extend to all such isomers and mixtures thereof.
As used in this specification, alone or in combination, the term “C
1-6
alkyl” refers to straight or branched chain alkyl moiety having from one to six carbon atoms, including for example, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl, hexyl and the like.
The term “C
2-6
alkenyl” refers to a straight or branched chain alkyl moiety having two to six carbon atoms and having in addition one double bond, of either E or Z stereochemistry where applicable. This term would include for example, vinyl, 1-propenyl, 1- and 2-butenyl, 2-methyl-2-propenyl etc.
The term “C
2-6
alkynyl” refers to a straight or branched chain alkyl moiety having two to six carbon atoms and having in addition one triple bond. This term would include for example, ethynyl, 1-propynyl, 1- and 2-butynyl, 1-methyl-2-butynyl etc.
The term “cycloalkyl” refers to a saturated alicyclic moiety having from three to eight, e.g. 3-6, carbon atoms and includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and bicyclo[2.2.1]heptanyl.
The term “cycloalkenyl” refers to an alicyclic moiety having from three to eight carbon atoms and having in addition one double bond. This term includes, for example, cyclopentenyl, cyclooctenyl and bicyclo[2.2.1]heptenyl.
The term “heterocycloalkyl” refers to a saturated heterocyclic moiety having from two to eight, e.g. 2-6, carbon atoms and one or more heteroatom from the group N, O, S (or oxidised versions thereof) which may be optionally benzofused at any available position. This includes, for example, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, benzodioxole and 8-oxabicyclo[3.2.1]octane.
The term “heterocycloalkenyl” refers to an alicyclic moiety having from three to eight carbon atoms and one or more heteroatoms selected from N, O, S and oxidised versions thereof, and having in addition one double bond. This term includes, for example, dihydropyranyl and 8-oxabicyclo[3.2.1]octene.
The term “aryl” refers to an aromatic carbocyclic radical having a si

Affiliated with

Also associated with

Rating

Hydroxamic and carboxylic acid derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Hydroxamic and carboxylic acid derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydroxamic and carboxylic acid derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2997965